UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Nov

20

Closing gaps in HS care through community engagement and scientific innovation

Read More Share:linkedin| twitter| email

Nov

20

UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

Nov

14

New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

Read More Share:linkedin| twitter| email

Nov

14

A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

Read More Share:linkedin| twitter| email

Oct

15

Powering the dreams of people impacted by myasthenia gravis (MG)

Read More Share:linkedin| twitter| email

Oct

15

UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.

Read More Share:linkedin| twitter| email

Oct

14

UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)

Read More Share:linkedin| twitter| email

Oct

11

UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Read More Share:linkedin| twitter| email

Sep

30

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

Read More Share:linkedin| twitter| email

Sep

27

UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)